Literature DB >> 9236676

Mycoplasmal arthritis in patients with primary immunoglobulin deficiency: clinical features and outcome in 18 patients.

A Franz1, A D Webster, P M Furr, D Taylor-Robinson.   

Abstract

A survey of 358 patients with primary antibody deficiency shows that mycoplasmal infection is the commonest cause of severe chronic erosive arthritis. We review our experience with 18 patients with confirmed or probable mycoplasmal arthritis. There was a broad spectrum of severity from a monoarthritis rapidly responding to tetracyclines to severe debilitating polyarthritis, sometimes with antibiotic-resistant organisms which in two cases were eliminated following hyperimmune animal serum therapy. Most patients had very low serum 1gG levels at the onset of arthritis, suggesting that maintaining levels within the normal range with immunoglobulin replacement may prevent infection. The unique susceptibility of these patients to mycoplasmal arthritis shows that antibodies play a crucial role in protection against these organisms.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9236676     DOI: 10.1093/rheumatology/36.6.661

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  24 in total

Review 1.  Selective IgA deficiency (SIgAD) and common variable immunodeficiency (CVID).

Authors:  L Hammarström; I Vorechovsky; D Webster
Journal:  Clin Exp Immunol       Date:  2000-05       Impact factor: 4.330

Review 2.  How can a causal role for small bacteria in chronic inflammatory arthritides be established or refuted?

Authors:  D Taylor-Robinson; A Keat
Journal:  Ann Rheum Dis       Date:  2001-03       Impact factor: 19.103

3.  International Consensus Document (ICON): Common Variable Immunodeficiency Disorders.

Authors:  Francisco A Bonilla; Isil Barlan; Helen Chapel; Beatriz T Costa-Carvalho; Charlotte Cunningham-Rundles; M Teresa de la Morena; Francisco J Espinosa-Rosales; Lennart Hammarström; Shigeaki Nonoyama; Isabella Quinti; John M Routes; Mimi L K Tang; Klaus Warnatz
Journal:  J Allergy Clin Immunol Pract       Date:  2015-11-07

4.  Antibodies to Protein but Not Glycolipid Structures Are Important for Host Defense against Mycoplasma pneumoniae.

Authors:  Patrick M Meyer Sauteur; Adrianus C J M de Bruijn; Catarina Graça; Anne P Tio-Gillen; Silvia C Estevão; Theo Hoogenboezem; Rudi W Hendriks; Christoph Berger; Bart C Jacobs; Annemarie M C van Rossum; Ruth Huizinga; Wendy W J Unger
Journal:  Infect Immun       Date:  2019-01-24       Impact factor: 3.441

5.  Juvenile spondyloarthropathies associated with Mycoplasma pneumoniae infection.

Authors:  Miroslav Harjacek; Jelena Ostojic; Oktavija Djakovic Rode
Journal:  Clin Rheumatol       Date:  2006-01-04       Impact factor: 2.980

6.  Diagnosis of ureaplasma urealyticum septic polyarthritis by PCR assay and electrospray ionization mass spectrometry in a patient with acute lymphoblastic leukemia.

Authors:  Marie Balsat; Lionel Galicier; Alain Wargnier; Sabine Pereyre; Raphaël Itzykson; Myriem Zouakh; Cécile Bébéar; Nicolas Boissel
Journal:  J Clin Microbiol       Date:  2014-06-23       Impact factor: 5.948

7.  Role for mannose binding lectin in the prevention of Mycoplasma infection.

Authors:  Renata M J Hamvas; Marina Johnson; Arine M Vlieger; Clare Ling; Andrea Sherriff; Angela Wade; Nigel J Klein; Malcolm W Turner; A David B Webster
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

8.  Chronic bronchitis in immunocompromised patients: association with a novel Mycoplasma species.

Authors:  D Webster; H Windsor; C Ling; D Windsor; D Pitcher
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-08-26       Impact factor: 3.267

Review 9.  Osteoarticular infectious complications in patients with primary immunodeficiencies.

Authors:  Katherine A Bloom; Danna Chung; Charlotte Cunningham-Rundles
Journal:  Curr Opin Rheumatol       Date:  2008-07       Impact factor: 5.006

Review 10.  Recognition, clinical diagnosis and management of patients with primary antibody deficiencies: a systematic review.

Authors:  P Wood; S Stanworth; J Burton; A Jones; D G Peckham; T Green; C Hyde; H Chapel
Journal:  Clin Exp Immunol       Date:  2007-06-12       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.